MA46176A - Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci - Google Patents

Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci

Info

Publication number
MA46176A
MA46176A MA046176A MA46176A MA46176A MA 46176 A MA46176 A MA 46176A MA 046176 A MA046176 A MA 046176A MA 46176 A MA46176 A MA 46176A MA 46176 A MA46176 A MA 46176A
Authority
MA
Morocco
Prior art keywords
azetidin
triazolo
compositions
methods
pyridinyl compounds
Prior art date
Application number
MA046176A
Other languages
English (en)
French (fr)
Inventor
Limin Cheng
Yun-Xing Cheng
Simon Charles Goodacre
Rongbao Hua
F Anthony Romero
Mark Zak
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA46176A publication Critical patent/MA46176A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA046176A 2016-09-06 2017-09-02 Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci MA46176A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2016098215 2016-09-06

Publications (1)

Publication Number Publication Date
MA46176A true MA46176A (fr) 2019-07-17

Family

ID=59761965

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046176A MA46176A (fr) 2016-09-06 2017-09-02 Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci

Country Status (19)

Country Link
US (3) US20190202822A1 (https=)
EP (2) EP3510030B1 (https=)
JP (1) JP7050761B2 (https=)
KR (1) KR20190045302A (https=)
CN (1) CN109890817B (https=)
AU (1) AU2017324281A1 (https=)
BR (1) BR112019004486A2 (https=)
CA (1) CA3035712A1 (https=)
CL (1) CL2019000568A1 (https=)
CO (1) CO2019002171A2 (https=)
CR (1) CR20190118A (https=)
IL (1) IL265153A (https=)
MA (1) MA46176A (https=)
MX (1) MX2019002627A (https=)
PE (1) PE20190632A1 (https=)
PH (1) PH12019500478A1 (https=)
RU (1) RU2019109570A (https=)
SG (1) SG11201901954XA (https=)
WO (1) WO2018046409A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020257143A1 (en) * 2019-06-18 2020-12-24 Genentech, Inc. Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2024148186A1 (en) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Polymorphs of a jak1/tyk2 inhibitor and uses thereof
WO2024148184A1 (en) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Compounds and processes for the preparation of jak inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
AU6311996A (en) 1995-07-06 1997-02-05 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
DE60214428T2 (de) 2001-12-20 2007-09-20 Bayer Healthcare Ag 1, 4-dihydro-1, 4-diphenylpyridin-derivate
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
EP2288260A4 (en) * 2008-06-20 2013-10-23 Genentech Inc TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
CN102459258B (zh) * 2009-06-05 2015-11-25 赛福伦公司 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
SMT201900223T1 (it) * 2013-05-17 2019-07-11 Incyte Corp Sale di bipirazolo come inibitore di jak
MA38884A1 (fr) 2013-09-05 2017-06-30 Hoffmann La Roche Composé de triazolopyridine, compositions et procédés d'utilisation associés
JP2018507236A (ja) * 2015-03-04 2018-03-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft トリアゾロピリジン化合物及びその使用法

Also Published As

Publication number Publication date
US20190202822A1 (en) 2019-07-04
RU2019109570A (ru) 2020-10-08
WO2018046409A1 (en) 2018-03-15
EP4198036A1 (en) 2023-06-21
IL265153A (en) 2019-05-30
PE20190632A1 (es) 2019-04-26
US20230242530A1 (en) 2023-08-03
EP3510030A1 (en) 2019-07-17
MX2019002627A (es) 2019-10-30
PH12019500478A1 (en) 2019-12-02
SG11201901954XA (en) 2019-04-29
KR20190045302A (ko) 2019-05-02
AU2017324281A1 (en) 2019-03-21
JP7050761B2 (ja) 2022-04-08
EP3510030B1 (en) 2023-03-22
CN109890817B (zh) 2022-06-17
RU2019109570A3 (https=) 2020-10-08
CR20190118A (es) 2019-04-30
CA3035712A1 (en) 2018-03-15
JP2019526593A (ja) 2019-09-19
CL2019000568A1 (es) 2019-07-12
CN109890817A (zh) 2019-06-14
CO2019002171A2 (es) 2019-05-21
US20200270248A1 (en) 2020-08-27
BR112019004486A2 (pt) 2019-05-28

Similar Documents

Publication Publication Date Title
HUS2200054I1 (hu) 2-fluor-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-B][1,2,4]triazin-2-il]benzamid tablettás kiszerelése
EP3500575C0 (en) CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE, ITS PREPARATION AND USES
EP3370715A4 (en) CHIMERIC COMPOUNDS PROVIDED AGAINST PROTEOLYSIS AND METHOD FOR THE PRODUCTION AND USE THEREOF
SI3107914T1 (sl) Pirazolo(1,5-A)pirimidin-5,7-diaminske spojine kot inhibitorji CDK in njihova terapevtska uporaba
DK3478682T3 (da) [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
SI3555097T1 (sl) Imidazo(4,5-d)pirolo(2,3-b)piridinske spojine kot zaviralci janus kinaz
MA49570A (fr) Composés bicycliques pyrazolo et triazolo utilisés en tant qu'inhibiteurs de kinase jak
EP3250572A4 (en) Substituted imidazo [1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
EP3458531A4 (en) COATING COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
EP3675848A4 (en) SPIROCYCLUS COMPOUNDS AND METHOD OF MANUFACTURING AND USING THEREOF
HUE037558T2 (hu) Imidazo[4,5-c]kinolin-2-on vegyületek és alkalmazásuk rák kezelésében
EP3484504A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE
EP3504196A4 (en) METHOD FOR PRODUCING OLAPARIB
PL3597649T3 (pl) Kompozycje zawierające podstawione związki [1,2,4]triazolo[1,5-a]pirymidyn-7-ylowe jako inhibitory pde2
MA50041A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
IL254168A0 (en) Use of 3,2-dihydroimidazo[2,1-c]converted quinazolines
EP3455226A4 (en) SPIROCYCLIC COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
MA47167A (fr) Composés pyrazolopyrimidine et leurs procédés d'utilisation
ZA201902781B (en) Compositions and methods for the treatment of xerostomia
LT3500571T (lt) Imidazo[1,2-a]piridino junginiai, juos apimančios kompozicijos, ligų gydymo būdai juos panaudojant, ir jų paruošimo būdai
MA46176A (fr) Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci
EP3349755A4 (en) NICOTINE FORMULATIONS AND PROCESS FOR THE PREPARATION AND USE THEREOF
EP3122381A4 (en) Use of activin receptor-like kinase 1 (alk-1) antagonists in the treatment of cancer
LT3230289T (lt) 7-(morfolinil)-2-(n-piperazinil)metiltieno[2, 3-c]piridino dariniai kaip priešvėžiniai vaistai
HK1249756A1 (zh) 用於治疗疾病的稠合双环化合物